Celesta Capital led the $16 million funding for cancer diagnosis startup OneCell Diagnostics. The round has also included Tenacity Ventures, Cedars Sinai, Eragon, and Singularity Ventures.

OneCell said in a press release that the proceeds will be used to expand the market for OncoIndx Alfa, a next-generation liquid biopsy test that detects circulating tumor cells.

OneCell uses next-generation sequencing, strong bioinformatics, AI/ML, and data analytics to create multi-omics biomarkers. The company was founded in 2021.

Mohan Uttarwar, CEO and co-founder of OneCell Diagnostics, said, "We see a future where everyone has access to high-quality, life-saving cancer testing and this funding is a powerful validation of our vision."

Rich biomarkers that advance precise diagnosis and treatment of cancer are included in use cases such as treatment response monitoring, disease progression, recurrence and more.

The website states that OneCell has a partnership with the All-India Institute of Medical Science and the Tata Memorial Centre. Strategic academic and industry partners include Harvard Medical School and Stanford University.

To date, the company has already introduced a series of products and tested its cell biopsy technology in nearly 10,000 patients in India. This extensive testing has provided valuable insights into the technology's effectiveness and potential for broader applications.

We have the opportunity to deliver accurate, personalized cancer care worldwide by integrating our single-cell multi-omics analytics with next-generation liquid biopsy approaches.

OneCell, founded in 2021, proprietary technology leverages a combination of next-generation sequencing in combination with strong bioinformatics, AI/ML, and data analytics for multi-omics biomarkers.